Objective    To investigate the anti-tumor pathway and the effect of recombinant E.coli. LLO/OVA in C57BL/6 mice.     Methods    Magnetic sorting of splenic CD11c

CD4

+

and CD8

+

T cell from immunized mice with E.coli. LLO/OVA and E.coli. OVA vaccination were performed. In addition

  the lymphocytes mixed reaction and IL-2 and IFN-γ in the supern

atant were detected. The percentage of OVA257-264 SIINFEKL specific CD8

+

T cell were checked by flow cytometry. B16-OVA melanoma protection and inhibition response in E.coli. vaccinated mice were compared.     Results    Compared to E.coli. OVA

E.coli. LLO/OVA-vaccinated splenic CD11c cells stimulated proliferation of autogenic CD4

+

T cells and IL-2 production of these cells. CD11c cells induced autogenic CD8

+

T cells proliferation and IFN-γ secretion. A great number of OVA257-264 SIINFEKL-specific splenic CD8

+

T cells were induced and the number of lung tumor nodules was significantly reduced in E.coli. LLO/OVA vaccinated mice.     Conclusion    Recombinant LLO

as an effective adjuvant of E.coli. OVA

can induce murine splenic CD11c cells activation and play potential roles on CD4

+

and CD8

+

T cells proliferation and IL-2 and IFN-γ secretion of these cells

induce more OVA-specific CD8

+

T cells and stimulate stronger tumor inhibition in vivo of vaccinated C57BL/6 mice.